NEW YORK – In vitro diagnostics company Todos Medical announced Thursday it has entered into an exclusive option agreement to acquire Provista Diagnostics.
Financial and other terms of the deal were not disclosed.
Provista is currently developing and commercializing its Videssa blood test for breast cancer, which has been clinically validated for early detection.
"The Videssa technology platform and the menu of cancer and autoantibodies tests from Provista Diagnostics represent a robust, reliable, cost- effective and clinically useful line of products for the early and accurate detection of breast cancer," said Jorge Leon, Todos' senior medical advisor.
Todos is purchasing Provista from Ascenda Biosciences, which purchased Provista in June.
Israel-based Todos also announced Gerald Commissiong as CEO and Daniel Hirsch as CFO, and the new executives will be in charge of relocating Todos from Israel to the US. The company will focus on US development and commercialization efforts of its Total Biochemical Infrared Analysis diagnostic platform. Former CEO Herman Weiss will stay on as chairman of the board of directors.